The European/Australasian stroke prevention in reversible ischaemia trial (ESPRIT) confirms that long-term administration of the combination acetylsalicylic acid and dipyridamole is more effective than acetylsalicylic acid in reducing the risk of vascular events after cerebral ischaemia of arterial origin. The results of this study in combination with the results of previous studies have provided sufficient evidence for the use of this therapy in clinical practice.